It is widely accepted that small molecule drugs, despite their selectivity at primary targets, exert pharmacological effects (and safety liabilities) through a multiplicity of pathways. As such, it has proven extremely difficult to experimentally assess polypharmacology in an agnostic fashion. Profiling of metabolites produced as part of physiological responses to pharmacological stimuli provides a unique opportunity to explore drug pharmacology. 122 eicosanoid lipids in human whole blood were monitored from 10 different donors upon stimulation with several inducers of immunological responses and treatment with modulators of prostaglandin (PG) and leukotriene (LT) biosynthesis, including clinical and investigational molecules. Such analysis revealed differentiation between drugs nominally targeting different eicosanoid biosynthetic enzymes, or even those designed to target the same enzyme. Profiled agents -some of them marketed products-affect eicosanoid biosynthesis in ways that cannot be predicted from information on their intended targets. As an example, we employed this platform to discriminate drugs based on their ability to silence PG biosynthesis in response to bacterial lipopolysaccharide (LPS), resulting in differential pharmacological activity in an in vivo model of endotoxemia. Some of the observed effects are subject to variability among individuals, indicating a potential application of this methodology to the patient stratification, based on their responses to bench mark drugs and experimental compounds read on the eicosanome via a simple blood test.
Introduction
The era of personalized and precision medicine for drug development has been heralded, with the lofty goal of utilizing a patient's unique genetic profile and disease status to find the right drug match. Several pharmaceutical and biotechnology companies are placing substantial effort in the development of such tailored therapeutics, with the prospects of significantly improved clinical outcomes: efficacy associated with reductions in adverse events (1, 2) .
While precision medicine shows already high potential for the discovery of highly efficacious, safer medicines, targeted drug development requires in-depth understanding of the mechanism of action (MOA) of experimental compounds, as well as robust systems for accurate profiling (and prediction) of therapeutic response. The systematic analysis of drugs that interact with more than one molecular target offers an opportunity to dissect the complexities of drug action, and constitutes the first step for the construction of computational models to predict polypharmacology (3, 4) . Advances in omics platforms over the past decade have enabled early exploration of global physiological perturbations (genome, proteome, metabolome, epigenome and lipidome) in health and disease, thus ushering the era of systems biology. Several approaches drawing from this emerging discipline have been utilized to build drug-target networks for complex diseases, involving multiple drugs acting on distinct targets. Those efforts have aided in the formulation of combinatorial therapy hypotheses (5, 6) . A less desirable, yet a central aspect to polypharmacology is ever-present off-target effects. One major reason for de-prioritization of candidate drugs is the discovery of toxicities, often during late pre-clinical profiling and clinical development stages. Emerging computational methodologies are starting to provide more efficient means to assess compound attributes and "drug-likeness" (7) . With the increasing availability of large pharmacological databases (8, 9) , in silico prediction algorithms are starting to provide a foundation for the analysis of interaction networks involving drugs, targets and anti-targets. Complementing in silico approaches, advances in analytical chemistry, particularly in the field of mass spectrometry, are enabling larger scale quantification of multiple analytes with unprecedented specificity, sensitivity and accuracy. In spite of by guest, on November 10, 2017 www.jlr.org Downloaded from this progress, methodologies applicable to clinical studies are still lacking the simplicity and throughput to become widely used. Once these hurdles are overcome, efficient, disease-focused platforms applicable for patient phenotyping will become essential for stratification based on biochemical differences in their responses to inducers of disease, and drug action.
Here we describe a molecular phenotyping study of human whole blood, by analysis of eicosanoid lipids derived from the conversion of membrane phospholipids to arachidonic acid (AA), an early and critical event in the initiation and establishment of multiple inflammatory responses. The biosynthesis of eicosanoids occurs well within an hour upon exposure of cells to a host of stimuli, providing an opportunity to take quick "snapshots" of metabolic pathways driving the production of lipid messengers.
We employed a high-throughput platform including an informatics workflow that allows unsupervised, simultaneous quantification of 122 eicosanoids in human whole blood, tissues, and other matrices (10).
Several researchers have reported previously on the systematic measurement of eicosanoid production in whole blood upon stimulation (11, 12) , yet the platform that we describe here offers higher resolution, sensitivity and throughput, making its application to clinical sample analysis, and compound screening or profiling for drug discovery, more practical. Covered lipids include PGs, TXs, LTs, eoxins, and lipoxins, shown to be sensitive immunological markers (13) (14) (15) . When used in survey mode, this platform can 
Methods
Compound treatments. Fresh heparinized human whole blood samples from donors that met the predefined election criteria (no anti-inflammatory treatments) were obtained from the Normal Blood Donor Service at the Scripps Research Institute on the day of experiment, and used immediately within 30min. HWB samples were processed as previously described (10) . Briefly, HWB samples were diluted 1:1 with RPMI-1640 medium and dispensed to 96-well plates at 200 μL/well. Each well was then pretreated with or without clinical and experimental molecules targeting PG and LT biosynthesis (Supplemental Table 3 Lipidomics profiling. An in-house developed UPLC-MS based lipidomics platform has been described previously (10) . Briefly, human whole blood samples from healthy donors subject to different treatments were processed employing 96-well format solid phase extraction. Extracted lipids were then subjected to simultaneous quantitative UPLC-MS analysis in scheduled MRM (sMRM) mode.
TNFα quantification in mouse blood. Mice were pre-dosed with compounds followed by intraperitoneal administration of LPS. Blood samples were drawn into after the animals were sacrificed. Levels of TNFα were then quantified employing ELISA kits (R&D Systems, Minneapolis, MN).
Data analysis and visualization. The absolute concentrations (pg/μL) of 122 eicosanoid lipids in individual sample were quantified, based on a calibration curve generated from serial diluted standard samples in each experiment, using our customized R-based quantification software. Data analysis, including principal component analyses (PCA)-based quality control (QC) process to detect outlier samples, differential production analysis of eicosanoid lipids in response to various biological perturbations and hierarchical clustering, were conducted using ArrayStudio V7.0 (www.omicsoft.com).
For visualization purposes, both the absolute concentrations of lipids under various biological conditions, and the ratios of lipids in response to various biological perturbations were log2 transformed, and presented in heat maps to reflect the expression profiles of multiple lipids under different conditions. including bacterial LPS, LTE4 and PGE2. LTE4 was chosen as it is a more stable Cys-LT with known immunomodulatory effects (16) and can drive neutrophilia in humans (17) . The changes in eicosanome in 2 donors induced by A23187 (included as a comparator), LPS, PGE2 and LTE4 are summarized in Figure 1 . In contrast to A23187, the LPS-induced eicosanome occurred with a delayed onset.
Upon application of LTE4 (up to 0.25 μg/mL) and PGE2 (up to 1 μg/ml) to whole blood, in addition to the added lipids, metabolites of both (such as EXE4, 11t-LTE4 of LTE4 and PGD2, PGJ2, PGE1 of PGE2) were detected throughout the time course study indicating metabolic conversion of the added eicosanoid. Surprisingly, LTE4 and PGE2 application also led to detectable changes in eicosanome perhaps consistent with their immunomodulatory activities (16) . Noteworthy are marked increases in PGD2 following application of PGE2. While no literature precedence exists for the conversion of PGE2 to PGD2, or induction of production of PGD2 by increased PGE2, our evaluation of experimental procedures has ruled out analytical artifacts (Supplemental Figure 2) . When we spiked d4-PGE2 (1μg/ml) in HWB, no d4-PGD2 was observed. But we noticed a significant increase in the concentrations of PGE2 metabolites previously detected such as PGD2, PGJ2, LXB4 and 11b-PGE2. Additional studies are needed to elucidate mechanisms of PGE2 dependent PGD2 production in human whole blood. Montelukast treatment in asthmatics with decreases in urinary LTE4 levels, a marker for systemic CysLT tone (33) . These findings also raise the question on the relative merits of targeting LTC4 synthase pathway as an alternative to CysLT receptor antagonism for treating CysLT driven pulmonary conditions.
We also performed a comparison of two 5-LO inhibitors, Zileuton (Zyflo™), a marketed drug that is efficacious in severe asthma, yet is not widely prescribed because of idiosyncratic elevations in liver enzymes (34) , and MK-0633 (35, 36) , an experimental molecule developed by Merck that did not show efficacy in asthma and chronic obstructive pulmonary disease (COPD) trials (40) . We used these two molecules to illustrate the remarkable differences that can be revealed between two inhibitory molecules targeting the same enzyme, 5-LO. MK-0633 has much higher potency relative to Zileuton in blocking the production of LOX pathway eicosanoids, and is more selective as well: Zileuton's off-target effects on the COX pathway lipids are more significant at the higher concentration range ( Figure 2C ). Given that MK-0633, a more selective 5-LOX inhibitor molecule with a superior physiochemical profile relative to Zileuton, did not meet efficacy end points in proof of concept studies in asthma and COPD asthma trial (36) , the data reveals that mechanisms in addition to 5-LOX inhibition, such a COX inhibition, contributes to the efficacy of Zileuton.
Inter-subject Variability. Blood samples from 23 human donors were analyzed to understand interindividual variability in A23187-induced eicosanoids (Supplemental Figure 3) . The results show remarkable variability in the levels of lipid production. The observed qualitative and quantitative differences in levels of specific PGs and LTs both in basal and stimulated conditions indicate that there is an individual "inflammatory response potential", which is readable through the eicosanome. To rule out the possible variations caused by cellular activations or sample handling artifacts, we also demonstrated that eicosanoid generation is not dependent upon time of sample processing after the blood was collected from donor. Over two hours of incubation at 37 °C, the primary eicosanoid levels remain relatively unchanged and no new metabolite was observed in the blood spiked with deuterated AA (Supplemental Figure 4) . Additionally, we took into account the donors' smoking status (37, 38) and dietary supplements intake in order to avoid the external inference with the eicosanoid levels. With 2 smokers and 1 person taking fish oil out of our 23 donors, the data showed no bias due to these two factors. The lower detection limits (LLODs) and upper detection limits (ULODs) of all the lipids in 10 donors were summarized in the Supplemental Table 1 , as well as their quantification ranges (pg/μL). The measured amounts of eicosanoids under stimulated conditions in human whole blood are consistent with reported levels (39) .
Most of the lipids exhibited inter-donor variation at the baseline measurements, which is intrinsic to the human blood studies. Because of the interest in baseline eicosanoid quantification, the standard curves were prepared in RPMI medium rather than blood; this could be a potential source of error/variation due to differential suppression from media and human blood. PG metabolites such as TXB2 and PGE2 have modulatory effects on TNFα synthesis and release.
Inhibition of thromboxane (TX) biosynthesis attenuates endotoxin-induced TNFα production (44) whereas PGE2 suppresses TNFα release, and blockade of PGE2 biosynthesis not only stimulates TNFα release, but prevents its breakdown (45, 46) . Therefore, it would not be possible to predict a priori the outcome of inhibiting COX pathway. The effect of combinatorial inhibition TXB2 and PGE2, on LPS induced release of cytokines such as TNFα: would need to be addressed in vivo. We set out to investigate the outcome of combinatorial inhibition of TXB2 and PGE2 on TNFα release in an endotoxemia model in vivo. We examined the effects of Indomethacin and Rofecoxib in LPS induced inflammation model in mouse with serum levels of TNFα as a biomarker of inflammatory response and, PGE2 and TXB2 levels as measures of COX pathway inhibition. For this, a sub-lethal dose of LPS was given to mice pre-dosed with Indomethacin, Rofecoxib or saline solution. Figure 4A shows that a limited lipidomics signature resembling the one detected with human whole blood was observable in blood samples from those animals, including elevations in TXB2 and PGE2. Again something that could not be predicted a priori, Indomethacin, but not Rofecoxib, induced a dramatic elevation in TNFα levels ( Figure 4B ). The serum levels of PGE2 ( Figure 4C ) showed strong negative correlation (r = -0.727) to those of TNFα, with a p value of 0.00006 ( Figure 4D ). This observation indicated that, in the mouse, up-regulation of TNFα production in response to LPS by inhibition of PGE2 biosynthesis may over-ride down-regulation expected from silencing of TXB2 biosynthesis. While NSAIDs are successfully used to treat several inflammatory conditions in clinical practice, the observations from the present study shed light on Our studies offer a great example of applying lipidomics profiling to drug discovery. Firstly we have a comprehensive, highly efficient eicosanoid panel that enables large-scale compound screening. Secondly, this is the first time to employ this eicosanoid panel to differentiate clinical molecules and demonstrate their distinct poly-pharmacology. Last but not least, this is also the first in the field to employ the platform to reveal TNFα pharmacology and investigate the individual differences in immune responses.
We envision the broad utility of the agonistic lipidomics profiling platform described here to complex biological problems, for example to defining lipidomics networks in health and disease, pharmacogenomics, hypotheses generation, pathway based drug discovery and re-purposing existing pharmacopoeia. In turn, we expect that information obtained from such profiling work will provide much needed complementary data to enable building more efficient networks that are today dominated by expression array data, lacking predictive value with regard to the actual production of proteins and modulation of their specific functions. These lessons, taken as a whole, provide an illustration for how precision medicine may become a reality, hopefully in the not-so-distant future. 
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